Skip to main content

Advertisement

Figure 5 | Cancer Cell International

Figure 5

From: The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis

Figure 5

Effects of ATO and nilotinib on the expressions of TAL1 and BTG1. Cells were treated with 1 μM ATO and 5 nM Nilotinib alone or in combination for 72 h. The mRNA (A) and protein (B) expressions of TAL1 and BTG1 were evaluated by RT-PCR and Western blotting, respectively. β-actin was used as an internal control, and representative data were presented. (A) 1, Control; 2, Nilotinib treatment alone; 3, ATO treatment alone; 4, Nilotinib + ATO. (B) 1, Control; 2, ATO treatment alone; 3, Nilotinib treatment alone; 4, Nilotinib + ATO.

Back to article page